cpp-acp (casein phosphopeptide-amorphous calcium phosphate)  (Recaldent Pty Ltd)

Journal: iScience

Article Title: Layer-by-layer coated probiotics with tannic acid-Ca 2+ and casein phosphopeptide complexes for caries prevention and enamel remineralization

doi: 10.1016/j.isci.2024.111579

Figure Lengend Snippet:

Article Snippet: Casein phosphopeptide (CPP) , Macklin , Cat#C918582.

Techniques: Recombinant, Phospho-proteomics, Saline, Modification, Staining, Software

Journal: NeuroImage

Article Title: The early stage of adult ocular dominance plasticity revealed by near-infrared optical imaging of intrinsic signals.

doi: 10.1016/j.neuroimage.2023.120122

Figure Lengend Snippet: Fig. 4. The early ocular dominance shift depends on activation of the NMDA receptor. (a) Schematic of the experimental design. During 4 days of monocular deprivation in adults, CPP was applied to block NMDA receptors. CPP treatment started after the eye was closed. (b) Representative experiments of mice differently treated by monocular deprivation and CPP are illustrated. The response magnitude maps from contralateral (left) and ipsilateral (middle) eyes are illustrated. The histogram of ocular dominance scores (right) is included. In the response magnitude maps, the lower right corner of the figure shows the response value. In the histogram of ocular dominance scores, the top left corner of the figure shows the ODI value. The scale bar is 0.5 mm. (c) ODIs detected by 630 nm (red circle) and 720 nm (blue circle) illuminations of each group (MD-CPP-, N = 8; MD-CPP+, N = 6; MD+CPP-, N = 6; MD+CPP+, N = 6). Data from the group without MD and CPP were taken from Fig. 1 for comparison. The bar indicates the average. The symbol “+ ” or “- ” represents the group with or without MD or CPP treatment. It is also applied to Fig. 4f. p < 0.001, two-way repeated measured ANOVA, Bonferroni’s multiple comparisons test. (d) Schematic of the experimental design for single-unit recording. (e) Ocular dominance histograms for cells (total, superficial and deep) from the MD-CPP+, MD+CPP- and MD+CPP+ groups. The CBIs of all three groups are indicated at the top right (MD-CPP+: total, 123 cells; superficial, 68 cells; deep, 47 cells. MD+CPP-: total, 148 cells; superficial, 75 cells; deep, 67 cells. MD+CPP+: total, 167 cells; superficial, 80 cells; deep, 72 cells). (f) Superficial and deep CBI scores for each group (MD-CPP-, N = 5; MD-CPP+, N = 5; MD+CPP-, N = 6; MD+CPP+, N = 7). They are shown as empty circles and diamonds, respectively. Data from the group without MD and CPP were taken from Fig. 3 for comparison. p < 0.001, two-way repeated measured ANOVA, Bonferroni’s multiple comparisons test. ∗ ∗ ∗ p < 0.001.

Article Snippet: CPP administration The NMDA receptor antagonist ( R,S ) − 3-(2-carboxypiperazin-4l)propyl-1-phosphonic acid (CPP) (HY-100,814, MedChemExpress) as used and prepared as previously described ( Sato and Stryker, 2008 ). pecifically, mice were intraperitoneally injected with 10 mg/kg in aline to a total volume of 0.2–0.25 mL.

Techniques: Activation Assay, Blocking Assay, Comparison, Single-unit Recording